PeptideDB

Alliin

CAS No.: 556-27-4

Alliin ((S)-3-(Allylsulphinyl)-L-alanine) is a garlic organosulfur compound that possesses various pharmacological prope
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Description Alliin ((S)-3-(Allylsulphinyl)-L-alanine) is a garlic organosulfur compound that possesses various pharmacological properties.alliin protected against LPS-induced ALI by activating PPARγ, which subsequently inhibited LPS-induced NF-κB activation and inflammatory response. Alliin might be used as an anti-inflammatory agent in the treatment of ALI.
In vivo LPS-induced ALI was induced in BALB/c mice by intranasal instillation of LPS.?Alliin was administered intraperitoneally to mice 1 h after LPS treatment.?Alliin markedly inhibited lung myeloperoxidase (MPO) activity and wet/dry (W/D) ratio induced by LPS.?Alliin also inhibited TNF-α and IL-1β in the bronchoalveolar lavage fluid (BALF) induced by LPS.?Furthermore, LPS-induced lung pathological injury was attenuated by treatment of alliin.?LPS-induced NF-κB activation was significantly inhibited by alliin.?In addition, the expression of peroxisome proliferator-activated receptor γ (PPARγ) was up-regulated by treatment of alliin.?Taken together,Alliin protected against LPS-induced ALI by activating PPARγ, which subsequently inhibited LPS-induced NF-κB activation and inflammatory response.
Synonyms 蒜氨酸, (S)-3-(Allylsulphinyl)-L-alanine
molecular weight 177.22
Molecular formula C6H11NO3S
CAS 556-27-4
Storage store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility DMSO: 3 mg/mL (16.92 mM)
References 1. Wang Y L , Guo X Y , He W , et al. Effects of alliin on LPS-induced acute lung injury by activating PPARγ[J]. Microbial Pathogenesis, 2017, 110:375-379. 2. Deng X, Yang P, Gao T, et al. Allicin attenuates myocardial apoptosis, inflammation and mitochondrial injury during hypoxia-reoxygenation: an in vitro study[J]. BMC Cardiovascular Disorders. 2021, 21(1): 1-9.